Showing results (581-590 of 610) with videos related to

Sort By:
Pageof 61
Cancer Research|July 22, 2020
BRG1 Loss Predisposes Lung Cancers to Replicative Stress and ATR DependencyManav Gupta, Carla P Concepcion, Caroline G Fahey, et al.
JCO Precision Oncology|October 30, 2018
Clinical Utility of Rapid EGFR Genotyping in Advanced Lung CancerIbiayi Dagogo-Jack, Christopher G Azzolli, Florian Fintelmann, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|March 9, 2021
Spectrum of Mechanisms of Resistance to Crizotinib and Lorlatinib in ROS1 Fusion-Positive Lung CancerJessica J Lin, Noura J Choudhury, Satoshi Yoda, et al.
JCO Precision Oncology|January 30, 2018
Tracking the Evolution of Resistance to ALK Tyrosine Kinase Inhibitors through Longitudinal Analysis of Circulating Tumor DNAIbiayi Dagogo-Jack, A Rose Brannon, Lorin A Ferris, et al.
Cancer Cell|October 8, 2021
Three subtypes of lung cancer fibroblasts define distinct therapeutic paradigmsHaichuan Hu, Zofia Piotrowska, Patricia J Hare, et al.
Cancer Discovery|September 28, 2018
Landscape of Acquired Resistance to Osimertinib in EGFR-Mutant NSCLC and Clinical Validation of Combined EGFR and RET Inhibition with Osimertinib and BLU-667 for Acquired RET FusionZofia Piotrowska, Hideko Isozaki, Jochen K Lennerz, et al.
Cancer Discovery|July 20, 2016
Molecular Mechanisms of Resistance to First- and Second-Generation ALK Inhibitors in ALK-Rearranged Lung CancerJustin F Gainor, Leila Dardaei, Satoshi Yoda, et al.
Cancer Cell|July 7, 2015
PF-06463922, an ALK/ROS1 Inhibitor, Overcomes Resistance to First and Second Generation ALK Inhibitors in Preclinical ModelsHelen Y Zou, Luc Friboulet, David P Kodack, et al.
Nature Medicine|March 6, 2018
SHP2 inhibition restores sensitivity in ALK-rearranged non-small-cell lung cancer resistant to ALK inhibitorsLeila Dardaei, Hui Qin Wang, Manrose Singh, et al.
Science Translational Medicine|April 5, 2013
Inertial focusing for tumor antigen-dependent and -independent sorting of rare circulating tumor cellsEmre Ozkumur, Ajay M Shah, Jordan C Ciciliano, et al.
Pageof 61